Skip to main content

Table 3 Baseline features of the patients

From: Adverse drug effects observed with vildagliptin versus pioglitazone or rosiglitazone in the treatment of patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials

Studies

Mean age (y)

Males (%)

HbA1c (%)

Duration of DM (y)

Bias risk assessment

 

Exp/cont

Exp/cont

Exp/cont

Exp/cont

 

Bolli 2008

57.0/56.3

64.1/61.7

8.4/8.4

6.4/6.4

B

Garber 2006

54.8/54.0

50.7/49.9

8.7/8.65

4.8/4.75

B

Kim 2010

49.2/49.8

83.3/88.9

8.7/8.6

2.1/1.9

B

Rosenstock 2007

54.2/54.5

57.6/57.5

8.7/8.7

2.7/2.3

B

Rosenstock 2009

54.2/54.4

54.5/57.6

8.63/8.58

2.60/1.98

B

  1. Abbreviations: Exp experimental group (pioglitazone or rosiglitazone), Cont control group (vildagliptin), y year, DM diabetes mellitus